Identification

Name
Lacidipine
Accession Number
DB09236
Type
Small Molecule
Groups
Approved, Investigational
Description

Lacidipine is a lipophilic dihydropyridine calcium antagonist with an intrinsically slow onset of activity. Due to its long duration of action, lacidipine does not lead to reflex tachycardia [1]. It displays specificity in the vascular smooth muscle, where it acts as an antihypertensive agent to dilate peripheral arterioles and reduce blood pressure. Compared to other dihydropyridine calcium antagonists, lacidipine exhibits a greater antioxidant activity which may confer potentially beneficial antiatherosclerotic effects [4]. Lacidipine is a highly lipophilic molecule that interacts with the biological membranes. Through radiotracer analysis, it was determined that lacidipine displays a high membrane partition coefficient leading to accumulation of the drug in the membrane and slow rate of membrane washout [3]. When visualized by small-angle X-ray diffraction with angstrom resolution to examine its location within the membranes, lacidipine was found deep within the membrane's hydrocarbon core [3]. These results may explain the long clinical half-life of lacidipine [3].

In randomised, well-controlled trials, administration of daily single-dose lacidipine ranging from 2-6 mg demonstrated comparable antihypertensive efficacy similar to that of other long-acting dihydropyridine calcium antagonists, thiazide diuretics, atenolol (a beta-blocker) and enalapril (an ACE inhibitor) [1]. It is available as once-daily oral tablets containing 2 or 4 mg of the active compound commonly marketed as Lacipil or Motens. It is not currently FDA-approved.

Structure
Thumb
Synonyms
Not Available
International/Other Brands
Caldine (Boehringer Ingelheim) / Lacimen (GlaxoSmithKline) / Lacipil (GSK) / Motens (Boehringer Ingelheim)
Categories
UNII
260080034N
CAS number
103890-78-4
Weight
Average: 455.551
Monoisotopic: 455.230787787
Chemical Formula
C26H33NO6
InChI Key
GKQPCPXONLDCMU-CCEZHUSRSA-N
InChI
InChI=1S/C26H33NO6/c1-8-31-24(29)21-16(3)27-17(4)22(25(30)32-9-2)23(21)19-13-11-10-12-18(19)14-15-20(28)33-26(5,6)7/h10-15,23,27H,8-9H2,1-7H3/b15-14+
IUPAC Name
3,5-diethyl 4-{2-[(1E)-3-(tert-butoxy)-3-oxoprop-1-en-1-yl]phenyl}-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C)C(=O)OCC

Pharmacology

Indication

Indicated for the treatment of hypertension either alone or in combination with other antihypertensive agents, including β-adrenoceptor antagonists, diuretics, and ACE-inhibitors [6].

Pharmacodynamics

acidipine is a specific and potent calcium antagonist with a predominant selectivity for calcium channels in the vascular smooth muscle. Its main action is to dilate predominantly peripheral and coronary arteries, reducing peripheral vascular resistance and lowering blood pressure [6].

Following the oral administration of 4 mg lacidipine to volunteer subjects, a minimal prolongation of QTc interval has been observed (mean QTcF increase between 3.44 and 9.60 ms in young and elderly volunteers) [6].

Mechanism of action

By blocking the voltage-dependent L-type calcium channels, it prevents the transmembrane calcium influx [2]. Normally, calcium ions serve as intracellular messengers or activators in exictable cells including vascular smooth muscles. The influx of calcium ultimately causes the excitation and depolarization of the tissues. Lacidipine inhibits the contractile function in the vascular smooth muscle and reduce blood pressure. Due to its high membrane partition coefficient, some studies suggest that lacidipine may reach the receptor via a two-step process; it first binds and accumulates in the membrane lipid bilayer and then diffuses within the membrane to the calcium channel receptor [5]. It is proposed that lacidipine preferentially blocks the inactivated state of the calcium channel [5].

Through its antioxidant properties shared amongst other dihydropyridine calcium channel blockers, lacidipine demonstrates an additional clinical benefit. Its antiatherosclerotic effects are mediated by suppressing the formation of reactive oxygen species (ROS) and subsequent inflammatory actions by chemokines, cytokines and adhesion molecules, thus reducing atherosclerotic lesion formation [4]. Lacidipine may also suppress cell proliferation and migration in smooth muscle cells and suppress the expression of matrix metalloproteinases, which affects the stability of atheromatous plaques [4].

TargetActionsOrganism
AVoltage dependent L type calcium channel
antagonist
Human
Absorption

Since it is a highly lipophilic compound, lacidpine is rapidly absorbed from the gastrointestinal tract following oral administration with the peak plasma concentrations reached between 30 and 150 minutes of dosing [6]. The peak plasma concentrations display large interindividual variability, with the values ranging from 1.6 to 5.7 μg/L following single-dose oral administration of lacidipine 4mg in healthy young volunteers [2].

Absolute bioavailability is less than 10% due to extensive first-pass metabolism in the liver [6].

Volume of distribution
Not Available
Protein binding

Lacidipine is highly protein-bound (more than 95%) to predominantly albumin and to a lesser extent, alpha-1-glycoprotein [6].

Metabolism

Lacidipine undergoes complete CYP3A4-mediated hepatic metabolism, with no parent drug detected in the urine or faeces. The 2 main metabolites have no pharmacological activity [2].

Route of elimination

Approximately 70% of the administered dose is eliminated as metabolites in the faeces and the remainder as metabolites in the urine [6].

Half life

The average terminal half-life of lacidipine ranges from between 13 and 19 hours at steady state [6].

Clearance
Not Available
Toxicity

There have been no recorded cases of lacidipine tablets overdosage. Some of the symptoms of overdose include prolonged peripheral vasodilation associated with hypotension and tachycardia. Bradycardia or prolonged AV conduction could theoretically occur. As there is no known antidote for lacidipine, the use of standard general measures for monitoring cardiac function and appropriate supportive and therapeutic measures is recommended [6].

Oral LD50 in mouse, rabbit and rat are 300mg/kg, 3200mg/kg and 980mg/kg, respectively [MSDS].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbafunginThe therapeutic efficacy of Abafungin can be increased when used in combination with Lacidipine.Investigational
AcebutololAcebutolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
AceclofenacThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Lacidipine.Approved, Vet Approved
Acetylsalicylic acidThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AlbaconazoleThe therapeutic efficacy of Albaconazole can be increased when used in combination with Lacidipine.Investigational
AlclofenacThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlcuroniumLacidipine may increase the neuromuscular blocking activities of Alcuronium.Experimental
AldesleukinAldesleukin may increase the hypotensive activities of Lacidipine.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Lacidipine.Approved, Investigational
AliskirenAliskiren may increase the hypotensive activities of Lacidipine.Approved, Investigational
AlminoprofenThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Alminoprofen.Experimental
AlprenololLacidipine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanLacidipine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineLacidipine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAmiloride may increase the hypotensive activities of Lacidipine.Approved
AminophenazoneThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Aminophenazone.Approved, Withdrawn
AmiodaroneAmiodarone may increase the hypotensive activities of Lacidipine.Approved, Investigational
AmitriptylineThe risk or severity of hypotension can be increased when Amitriptyline is combined with Lacidipine.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Lacidipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Lacidipine.Approved, Illicit
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Lacidipine.Approved
Amphotericin BAmphotericin B may increase the hypotensive activities of Lacidipine.Approved, Investigational
AmprenavirThe metabolism of Lacidipine can be decreased when combined with Amprenavir.Approved, Investigational
Amyl NitriteAmyl Nitrite may increase the hypotensive activities of Lacidipine.Approved
AntipyrineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Antipyrine.Approved, Investigational
AntrafenineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Antrafenine.Approved
ApalutamideThe serum concentration of Lacidipine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineApomorphine may increase the hypotensive activities of Lacidipine.Approved, Investigational
ApraclonidineApraclonidine may increase the hypotensive activities of Lacidipine.Approved
AprepitantThe serum concentration of Lacidipine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Lacidipine.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Lacidipine.Approved, Investigational
ArotinololArotinolol may increase the hypotensive activities of Lacidipine.Investigational
Arsenic trioxideArsenic trioxide may increase the hypotensive activities of Lacidipine.Approved, Investigational
AsenapineThe risk or severity of hypotension can be increased when Asenapine is combined with Lacidipine.Approved
AtazanavirThe serum concentration of Lacidipine can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Lacidipine.Approved
AtracuriumLacidipine may increase the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateLacidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AvanafilAvanafil may increase the antihypertensive activities of Lacidipine.Approved
AzapropazoneThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Azapropazone.Withdrawn
Azilsartan medoxomilAzilsartan medoxomil may increase the hypotensive activities of Lacidipine.Approved, Investigational
BaclofenBaclofen may increase the hypotensive activities of Lacidipine.Approved
BalsalazideThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Lacidipine.Experimental
BarbitalBarbital may increase the hypotensive activities of Lacidipine.Illicit
BarnidipineBarnidipine may increase the hypotensive activities of Lacidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Lacidipine.Approved, Investigational
BenazeprilatLacidipine may increase the hypotensive activities of Benazeprilat.Experimental
BendazacThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Bendazac.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Lacidipine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Lacidipine.Withdrawn
BenorilateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzydamineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Benzydamine.Approved
BepridilBepridil may increase the hypotensive activities of Lacidipine.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Lacidipine.Approved
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Lacidipine.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Lacidipine.Experimental
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Lacidipine.Approved, Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Lacidipine.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Lacidipine.Approved
BisoprololBisoprolol may increase the hypotensive activities of Lacidipine.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Lacidipine.Approved
BoceprevirThe serum concentration of Lacidipine can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibBortezomib may increase the hypotensive activities of Lacidipine.Approved, Investigational
BosentanThe serum concentration of Lacidipine can be decreased when it is combined with Bosentan.Approved, Investigational
BQ-123Lacidipine may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the hypotensive activities of Lacidipine.Approved
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Lacidipine.Approved, Investigational
BrimonidineBrimonidine may increase the hypotensive activities of Lacidipine.Approved
BromfenacThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Bromfenac.Approved
BromocriptineBromocriptine may increase the hypotensive activities of Lacidipine.Approved, Investigational
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Lacidipine.Investigational
BufexamacThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Bufexamac.Approved, Experimental
BumadizoneThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Bumadizone.Experimental
BumetanideBumetanide may increase the hypotensive activities of Lacidipine.Approved
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Lacidipine.Investigational
BupivacaineBupivacaine may increase the hypotensive activities of Lacidipine.Approved, Investigational
BupranololLacidipine may increase the hypotensive activities of Bupranolol.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Lacidipine.Approved
CadralazineCadralazine may increase the hypotensive activities of Lacidipine.Experimental
Calcium AcetateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium Phosphate.Approved
CanagliflozinCanagliflozin may increase the hypotensive activities of Lacidipine.Approved
CandesartanLacidipine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Lacidipine.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Lacidipine.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Lacidipine.Approved
CarbamazepineThe serum concentration of Lacidipine can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbetocinCarbetocin may increase the hypotensive activities of Lacidipine.Approved, Investigational
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Lacidipine.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Lacidipine.Withdrawn
CarprofenThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Lacidipine.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Lacidipine.Approved, Investigational
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Lacidipine.Approved, Investigational, Nutraceutical, Vet Approved
CelecoxibThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
CeritinibThe serum concentration of Lacidipine can be increased when it is combined with Ceritinib.Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
ChlorpromazineChlorpromazine may increase the hypotensive activities of Lacidipine.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Lacidipine.Approved
Choline magnesium trisalicylateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CicletanineLacidipine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Lacidipine.Approved
CilnidipineCilnidipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
CimicoxibThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Cimicoxib.Investigational
CisatracuriumLacidipine may increase the neuromuscular blocking activities of Cisatracurium.Approved
ClarithromycinThe serum concentration of Lacidipine can be increased when it is combined with Clarithromycin.Approved
ClevidipineClevidipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
ClofarabineClofarabine may increase the hypotensive activities of Lacidipine.Approved, Investigational
ClomipramineClomipramine may increase the hypotensive activities of Lacidipine.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Lacidipine.Approved
ClonixinThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Clonixin.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Lacidipine.Approved
CloranololLacidipine may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe serum concentration of Lacidipine can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the hypotensive activities of Lacidipine.Approved
CobicistatThe serum concentration of Lacidipine can be increased when it is combined with Cobicistat.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Lacidipine.Approved, Investigational
CrizotinibThe metabolism of Lacidipine can be decreased when combined with Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Lacidipine.Approved
CurcuminThe serum concentration of Lacidipine can be increased when it is combined with Curcumin.Approved, Investigational
CyclopenthiazideLacidipine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Lacidipine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Lacidipine.Approved
DabrafenibThe serum concentration of Lacidipine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DanazolThe metabolism of Lacidipine can be decreased when combined with Danazol.Approved
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Lacidipine.Approved, Investigational, Withdrawn
DantroleneThe risk or severity of adverse effects can be increased when Lacidipine is combined with Dantrolene.Approved, Investigational
DapagliflozinDapagliflozin may increase the hypotensive activities of Lacidipine.Approved
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Lacidipine.Approved
DarunavirThe serum concentration of Lacidipine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Lacidipine can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Lacidipine.Approved, Investigational
DeferasiroxThe serum concentration of Lacidipine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilLacidipine may increase the hypotensive activities of Delapril.Investigational
DelavirdineThe serum concentration of Lacidipine can be increased when it is combined with Delavirdine.Approved
DeserpidineLacidipine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneDesflurane may increase the hypotensive activities of Lacidipine.Approved
DexamethasoneThe serum concentration of Lacidipine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexibuprofenThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Dexibuprofen.Approved, Investigational
DexketoprofenThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Dexketoprofen.Approved, Investigational
DexmedetomidineDexmedetomidine may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
DexniguldipineLacidipine may increase the hypotensive activities of Dexniguldipine.Experimental
DiazoxideDiazoxide may increase the hypotensive activities of Lacidipine.Approved
DiclofenacThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideDiclofenamide may increase the hypotensive activities of Lacidipine.Approved, Investigational
DiethylnorspermineDiethylnorspermine may increase the hypotensive activities of Lacidipine.Investigational
DifenpiramideThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Difenpiramide.Experimental
DiflunisalThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Diflunisal.Approved, Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Lacidipine.Approved, Investigational
DihydroergotamineThe risk or severity of hypotension can be increased when Dihydroergotamine is combined with Lacidipine.Approved, Investigational
DiltiazemThe serum concentration of Lacidipine can be increased when it is combined with Diltiazem.Approved, Investigational
DinutuximabDinutuximab may increase the hypotensive activities of Lacidipine.Approved, Investigational
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Lacidipine.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Lacidipine.Approved
DoxacuriumLacidipine may increase the neuromuscular blocking activities of Doxacurium.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Lacidipine.Approved
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Lacidipine.Approved, Investigational
DoxycyclineThe serum concentration of Lacidipine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Lacidipine.Approved
DroperidolThe risk or severity of hypotension can be increased when Droperidol is combined with Lacidipine.Approved, Vet Approved
DroxicamThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Droxicam.Withdrawn
DuloxetineLacidipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Lacidipine.Approved
EfavirenzThe serum concentration of Lacidipine can be increased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Lacidipine.Approved
EfonidipineEfonidipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
EmpagliflozinEmpagliflozin may increase the hypotensive activities of Lacidipine.Approved
EnalaprilEnalapril may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the hypotensive activities of Lacidipine.Approved
EndralazineEndralazine may increase the hypotensive activities of Lacidipine.Experimental
EnzalutamideThe serum concentration of Lacidipine can be decreased when it is combined with Enzalutamide.Approved
EpanololLacidipine may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Epirizole.Approved
EplerenoneEplerenone may increase the hypotensive activities of Lacidipine.Approved
EprosartanEprosartan may increase the hypotensive activities of Lacidipine.Approved
ErgotamineThe risk or severity of hypotension can be increased when Ergotamine is combined with Lacidipine.Approved
ErythromycinThe metabolism of Lacidipine can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololLacidipine may increase the hypotensive activities of Esatenolol.Experimental
EsmololEsmolol may increase the hypotensive activities of Lacidipine.Approved
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Lacidipine.Approved, Investigational
EthanolEthanol may increase the hypotensive activities of Lacidipine.Approved
EthenzamideThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Ethenzamide.Experimental
EtodolacThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Etofenamate.Approved, Investigational
EtoricoxibThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Lacidipine can be decreased when it is combined with Etravirine.Approved
FelbinacThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Felbinac.Experimental
FelodipineFelodipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Lacidipine.Approved
FenoprofenThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Fenoprofen.Approved
FentiazacThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Fentiazac.Experimental
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Lacidipine.Experimental
FeprazoneThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Feprazone.Experimental
Ferulic acidFerulic acid may increase the hypotensive activities of Lacidipine.Experimental
FimasartanFimasartan may increase the hypotensive activities of Lacidipine.Approved, Investigational
FirocoxibThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Firocoxib.Experimental, Vet Approved
FloctafenineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Floctafenine.Approved, Withdrawn
FluconazoleThe metabolism of Lacidipine can be decreased when combined with Fluconazole.Approved, Investigational
FlunixinThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Flunoxaprofen.Experimental
FlupentixolThe risk or severity of hypotension can be increased when Flupentixol is combined with Lacidipine.Approved, Investigational, Withdrawn
FlurbiprofenThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Lacidipine.Experimental
FluvoxamineThe metabolism of Lacidipine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Lacidipine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Lacidipine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilFosinopril may increase the hypotensive activities of Lacidipine.Approved
FosinoprilatLacidipine may increase the hypotensive activities of Fosinoprilat.Experimental
FosphenytoinThe serum concentration of Lacidipine can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FostamatinibFostamatinib may increase the antihypertensive activities of Lacidipine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Lacidipine.Approved, Investigational, Vet Approved
FurosemideFurosemide may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Lacidipine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GallamineLacidipine may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideLacidipine may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Lacidipine.Approved, Investigational
GuacetisalThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Lacidipine.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Lacidipine.Approved
GuanazodineLacidipine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Lacidipine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Lacidipine.Approved, Investigational
GuanoclorLacidipine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzLacidipine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanLacidipine may increase the hypotensive activities of Guanoxan.Experimental
HalothaneHalothane may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Lacidipine.Experimental
HexamethoniumHexamethonium may increase the hypotensive activities of Lacidipine.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Lacidipine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Lacidipine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Lacidipine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Lacidipine.Approved, Investigational
IbuprofenThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Ibuproxam.Withdrawn
IcosapentThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Icosapent.Approved, Nutraceutical
IdelalisibThe serum concentration of Lacidipine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Lacidipine.Approved
ImatinibThe metabolism of Lacidipine can be decreased when combined with Imatinib.Approved
ImidaprilImidapril may increase the hypotensive activities of Lacidipine.Investigational
Imidazole salicylateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Imidazole salicylate.Experimental
ImipramineImipramine may increase the hypotensive activities of Lacidipine.Approved
IndapamideIndapamide may increase the hypotensive activities of Lacidipine.Approved
IndenololIndenolol may increase the hypotensive activities of Lacidipine.Withdrawn
IndinavirThe serum concentration of Lacidipine can be increased when it is combined with Indinavir.Approved
IndobufenThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Lacidipine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Lacidipine.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Lacidipine.Approved, Investigational
IsavuconazoleThe serum concentration of Lacidipine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Lacidipine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Lacidipine.Approved
IsofluraneIsoflurane may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
IsoniazidThe metabolism of Lacidipine can be decreased when combined with Isoniazid.Approved, Investigational
Isosorbide DinitrateIsosorbide Dinitrate may increase the hypotensive activities of Lacidipine.Approved, Investigational
Isosorbide MononitrateIsosorbide Mononitrate may increase the hypotensive activities of Lacidipine.Approved
IsoxicamThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineIsoxsuprine may increase the hypotensive activities of Lacidipine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
ItraconazoleThe serum concentration of Lacidipine can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Lacidipine can be increased when it is combined with Ivacaftor.Approved
KebuzoneThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Lacidipine.Investigational
KetoconazoleThe serum concentration of Lacidipine can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Ketorolac.Approved
LabetalolLabetalol may increase the hypotensive activities of Lacidipine.Approved
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Lacidipine.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Lacidipine.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Lacidipine.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LevobunololLevobunolol may increase the hypotensive activities of Lacidipine.Approved
LevobupivacaineLevobupivacaine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LevodopaLevodopa may increase the hypotensive activities of Lacidipine.Approved
LevosimendanLevosimendan may increase the hypotensive activities of Lacidipine.Approved, Investigational
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Lacidipine.Approved
LinezolidLinezolid may increase the hypotensive activities of Lacidipine.Approved, Investigational
LinsidomineLacidipine may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Lacidipine.Approved, Investigational
LofexidineLofexidine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LonazolacThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Lonazolac.Experimental
LopinavirThe serum concentration of Lacidipine can be increased when it is combined with Lopinavir.Approved
LornoxicamThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Lacidipine can be increased when it is combined with Lorpiprazole.Approved
LosartanLosartan may increase the hypotensive activities of Lacidipine.Approved
LovastatinThe metabolism of Lacidipine can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Lacidipine.Approved, Investigational
LuliconazoleThe serum concentration of Lacidipine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Lacidipine can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MacitentanLacidipine may increase the hypotensive activities of Macitentan.Approved
Magnesium carbonateThe therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Lacidipine.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Lacidipine.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Lacidipine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Lacidipine is combined with Magnesium oxide.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Lacidipine.Experimental
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Lacidipine is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Lacidipine is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineLacidipine may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolMannitol may increase the hypotensive activities of Lacidipine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Lacidipine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Lacidipine.Approved, Investigational
Meclofenamic acidThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Mefenamic acid.Approved
MeloxicamThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Metamizole.Approved, Investigational, Withdrawn
MethazolamideMethazolamide may increase the hypotensive activities of Lacidipine.Approved
MethohexitalMethohexital may increase the hypotensive activities of Lacidipine.Approved
MethoserpidineLacidipine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Lacidipine.Approved, Investigational
MethyclothiazideMethyclothiazide may increase the hypotensive activities of Lacidipine.Approved
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Lacidipine.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Lacidipine.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Lacidipine.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Lacidipine.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Lacidipine.Approved
MetipranololMetipranolol may increase the hypotensive activities of Lacidipine.Approved
MetocurineLacidipine may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideLacidipine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MetolazoneMetolazone may increase the hypotensive activities of Lacidipine.Approved
MetoprololMetoprolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
MetyrosineLacidipine may increase the hypotensive activities of Metyrosine.Approved
MibefradilThe serum concentration of Lacidipine can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Lacidipine can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MifepristoneThe serum concentration of Lacidipine can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Lacidipine.Approved
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Lacidipine.Approved, Vet Approved
MinoxidilMinoxidil may increase the hypotensive activities of Lacidipine.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Lacidipine.Investigational
MitotaneThe serum concentration of Lacidipine can be decreased when it is combined with Mitotane.Approved
MivacuriumLacidipine may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Lacidipine.Approved, Investigational
ModafinilThe serum concentration of Lacidipine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Lacidipine.Approved
MofebutazoneThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Lacidipine.Approved, Investigational
MorniflumateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Morniflumate.Approved
MorphineMorphine may increase the hypotensive activities of Lacidipine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Lacidipine.Approved, Investigational
MuzolimineLacidipine may increase the hypotensive activities of Muzolimine.Experimental
NabiloneNabilone may increase the hypotensive activities of Lacidipine.Approved, Investigational
NabumetoneThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Nabumetone.Approved
NadololNadolol may increase the hypotensive activities of Lacidipine.Approved
NafcillinThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftopidilLacidipine may increase the hypotensive activities of Naftopidil.Investigational
NaloxoneThe serum concentration of Lacidipine can be increased when it is combined with Naloxone.Approved, Vet Approved
NaproxenThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Naproxen.Approved, Vet Approved
NebivololNebivolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
NefazodoneThe serum concentration of Lacidipine can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Lacidipine can be increased when it is combined with Nelfinavir.Approved
NepafenacThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Nepafenac.Approved, Investigational
NesiritideNesiritide may increase the hypotensive activities of Lacidipine.Approved, Investigational
NetupitantThe serum concentration of Lacidipine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Lacidipine can be decreased when it is combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Lacidipine.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Lacidipine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Lacidipine.Approved, Investigational
NifedipineNifedipine may increase the hypotensive activities of Lacidipine.Approved
NifenazoneThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Lacidipine.Experimental
NilotinibThe serum concentration of Lacidipine can be increased when it is combined with Nilotinib.Approved, Investigational
NilvadipineNilvadipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
NimesulideThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Lacidipine.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
Nitric OxideNitric Oxide may increase the hypotensive activities of Lacidipine.Approved
NitroaspirinThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinNitroglycerin may increase the hypotensive activities of Lacidipine.Approved, Investigational
NitroprussideLacidipine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous acidNitrous acid may increase the hypotensive activities of Lacidipine.Approved, Investigational
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Lacidipine.Approved
NS-398The therapeutic efficacy of Lacidipine can be decreased when used in combination with NS-398.Experimental
ObinutuzumabLacidipine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Lacidipine.Withdrawn
OlanzapineThe risk or severity of hypotension can be increased when Olanzapine is combined with Lacidipine.Approved, Investigational
OlaparibThe metabolism of Lacidipine can be decreased when combined with Olaparib.Approved
OlmesartanOlmesartan may increase the hypotensive activities of Lacidipine.Approved, Investigational
OlsalazineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Olsalazine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Lacidipine.Investigational
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Lacidipine.Experimental
OsimertinibThe serum concentration of Lacidipine can be increased when it is combined with Osimertinib.Approved
OxaprozinThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Oxaprozin.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Lacidipine.Approved
OxprenololOxprenolol may increase the hypotensive activities of Lacidipine.Approved
OxyphenbutazoneThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Lacidipine.Investigational, Withdrawn
PaclitaxelPaclitaxel may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
PalbociclibThe serum concentration of Lacidipine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of hypotension can be increased when Paliperidone is combined with Lacidipine.Approved
PancuroniumLacidipine may increase the neuromuscular blocking activities of Pancuronium.Approved
PapaverinePapaverine may increase the hypotensive activities of Lacidipine.Approved, Investigational
ParecoxibThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Lacidipine.Approved
Patent BlueThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Patent Blue.Approved
PenbutololPenbutolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Lacidipine.Experimental
PentobarbitalThe serum concentration of Lacidipine can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Lacidipine.Approved
PerindoprilPerindopril may increase the hypotensive activities of Lacidipine.Approved
PerindoprilatLacidipine may increase the hypotensive activities of Perindoprilat.Experimental
PheniprazinePheniprazine may increase the hypotensive activities of Lacidipine.Withdrawn
PhenobarbitalThe serum concentration of Lacidipine can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Lacidipine.Approved, Withdrawn
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Lacidipine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Lacidipine.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Lacidipine.Approved
PhenylbutazoneThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenytoinThe serum concentration of Lacidipine can be decreased when it is combined with Phenytoin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Lacidipine.Approved
PinacidilPinacidil may increase the hypotensive activities of Lacidipine.Approved
PindololPindolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
PipamperonePipamperone may increase the hypotensive activities of Lacidipine.Approved, Investigational
PipecuroniumLacidipine may increase the neuromuscular blocking activities of Pipecuronium.Approved
PirlindolePirlindole may increase the hypotensive activities of Lacidipine.Approved
PiroxicamThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Pirprofen.Experimental
PitolisantThe serum concentration of Lacidipine can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Lacidipine.Withdrawn
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Lacidipine.Approved
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Lacidipine.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Lacidipine.Approved, Investigational
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Lacidipine.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Lacidipine.Approved, Vet Approved
PolythiazidePolythiazide may increase the hypotensive activities of Lacidipine.Approved
PosaconazoleThe serum concentration of Lacidipine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Lacidipine.Approved, Investigational
PractololLacidipine may increase the hypotensive activities of Practolol.Approved
PramipexolePramipexole may increase the hypotensive activities of Lacidipine.Approved, Investigational
PranoprofenThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Lacidipine.Approved
PrimidoneThe serum concentration of Lacidipine can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Proglumetacin.Experimental
PromazineThe risk or severity of hypotension can be increased when Promazine is combined with Lacidipine.Approved, Vet Approved
PropacetamolThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Propacetamol.Approved, Investigational
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Lacidipine.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Lacidipine.Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Lacidipine.Approved, Investigational
PropofolPropofol may increase the hypotensive activities of Lacidipine.Approved, Investigational, Vet Approved
PropyphenazoneThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Proquazone.Experimental
PrucaloprideThe therapeutic efficacy of Prucalopride can be decreased when used in combination with Lacidipine.Approved
QuetiapineQuetiapine may increase the hypotensive activities of Lacidipine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Lacidipine.Approved, Investigational
QuinaprilatLacidipine may increase the hypotensive activities of Quinaprilat.Experimental
QuinidineThe risk or severity of hypotension can be increased when Quinidine is combined with Lacidipine.Approved, Investigational
QuinineThe serum concentration of Lacidipine can be decreased when it is combined with Quinine.Approved
RamiprilRamipril may increase the hypotensive activities of Lacidipine.Approved
RamiprilatLacidipine may increase the hypotensive activities of Ramiprilat.Experimental
RapacuroniumLacidipine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RavuconazoleThe therapeutic efficacy of Ravuconazole can be increased when used in combination with Lacidipine.Investigational
RemifentanilRemifentanil may increase the hypotensive activities of Lacidipine.Approved
RemikirenRemikiren may increase the hypotensive activities of Lacidipine.Approved
RescinnamineLacidipine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Lacidipine.Approved, Investigational
RifampicinThe serum concentration of Lacidipine can be decreased when it is combined with Rifampicin.Approved
RifamycinThe serum concentration of Lacidipine can be decreased when it is combined with Rifamycin.Investigational
RifapentineThe serum concentration of Lacidipine can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Lacidipine can be decreased when it is combined with Rifaximin.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Lacidipine.Approved, Investigational
RimexoloneThe serum concentration of Lacidipine can be decreased when it is combined with Rimexolone.Approved
RiociguatRiociguat may increase the hypotensive activities of Lacidipine.Approved
RisperidoneLacidipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe serum concentration of Lacidipine can be increased when it is combined with Ritonavir.Approved, Investigational
RituximabLacidipine may increase the hypotensive activities of Rituximab.Approved
RobenacoxibThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Robenacoxib.Experimental, Vet Approved
RocuroniumLacidipine may increase the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Rofecoxib.Approved, Investigational, Withdrawn
RopiniroleRopinirole may increase the hypotensive activities of Lacidipine.Approved, Investigational
RopivacaineRopivacaine may increase the hypotensive activities of Lacidipine.Approved
RotigotineRotigotine may increase the hypotensive activities of Lacidipine.Approved
SacubitrilSacubitril may increase the hypotensive activities of Lacidipine.Approved
SafinamideSafinamide may increase the hypotensive activities of Lacidipine.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Lacidipine.Withdrawn
SalicylamideThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Salsalate.Approved
SaprisartanSaprisartan may increase the hypotensive activities of Lacidipine.Experimental
SaquinavirThe serum concentration of Lacidipine can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Sarilumab.Approved, Investigational
SC-236The therapeutic efficacy of Lacidipine can be decreased when used in combination with SC-236.Experimental, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
SelexipagLacidipine may increase the hypotensive activities of Selexipag.Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Lacidipine.Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Lacidipine.Approved, Investigational
SevofluraneSevoflurane may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Lacidipine.Approved, Investigational
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Lacidipine.Approved
SiltuximabThe serum concentration of Lacidipine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Lacidipine can be increased when it is combined with Simeprevir.Approved
SitaxentanLacidipine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Lacidipine.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Lacidipine.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Lacidipine.Approved
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Lacidipine.Approved
SotalolSotalol may increase the hypotensive activities of Lacidipine.Approved
SpiraprilSpirapril may increase the hypotensive activities of Lacidipine.Approved
SpironolactoneSpironolactone may increase the hypotensive activities of Lacidipine.Approved
St. John's WortThe serum concentration of Lacidipine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Lacidipine can be increased when it is combined with Stiripentol.Approved
StreptokinaseStreptokinase may increase the hypotensive activities of Lacidipine.Approved, Investigational
SufentanilSufentanil may increase the hypotensive activities of Lacidipine.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Lacidipine.Approved
SulfasalazineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Sulindac.Approved, Investigational
SuprofenThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Suxibuzone.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Lacidipine.Approved, Investigational
TalinololLacidipine may increase the hypotensive activities of Talinolol.Investigational
TalniflumateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Talniflumate.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Lacidipine.Approved, Investigational
TegaserodThe therapeutic efficacy of Tegaserod can be decreased when used in combination with Lacidipine.Approved, Investigational, Withdrawn
TelaprevirThe serum concentration of Lacidipine can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Lacidipine can be increased when it is combined with Telithromycin.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Lacidipine.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Lacidipine.Experimental, Investigational
TenidapThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinTerazosin may increase the hypotensive activities of Lacidipine.Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Lacidipine.Approved
TetrahydropalmatineLacidipine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThalidomide may increase the hypotensive activities of Lacidipine.Approved, Investigational, Withdrawn
TheophyllineTheophylline may increase the antihypertensive activities of Lacidipine.Approved
ThiamylalThiamylal may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Lacidipine.Approved
ThioridazineThioridazine may increase the hypotensive activities of Lacidipine.Approved, Withdrawn
Tiaprofenic acidThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Tiaprofenic acid.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Lacidipine.Withdrawn
TimololTimolol may increase the hypotensive activities of Lacidipine.Approved
TinoridineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Tinoridine.Investigational
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Lacidipine.Approved
TipranavirThe serum concentration of Lacidipine can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the hypotensive activities of Lacidipine.Approved, Investigational
TocilizumabThe serum concentration of Lacidipine can be decreased when it is combined with Tocilizumab.Approved
TocopherylquinoneLacidipine may increase the hypotensive activities of Tocopherylquinone.Experimental, Investigational
TolazolineTolazoline may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
TolcaponeTolcapone may increase the hypotensive activities of Lacidipine.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
TolmetinThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Tolmetin.Approved
TolonidineLacidipine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Lacidipine.Approved
TorasemideTorasemide may increase the hypotensive activities of Lacidipine.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Lacidipine.Approved
TravoprostTravoprost may increase the hypotensive activities of Lacidipine.Approved
TrazodoneThe risk or severity of hypotension can be increased when Trazodone is combined with Lacidipine.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Lacidipine.Approved, Investigational
TretinoinTretinoin may increase the hypotensive activities of Lacidipine.Approved, Investigational, Nutraceutical
TriamtereneTriamterene may increase the hypotensive activities of Lacidipine.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Lacidipine.Approved, Investigational
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Lacidipine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Lacidipine.Approved, Investigational
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Lacidipine.Approved
Trolamine salicylateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Trolamine salicylate.Approved
TroleandomycinThe serum concentration of Lacidipine can be increased when it is combined with Troleandomycin.Approved
TubocurarineLacidipine may increase the neuromuscular blocking activities of Tubocurarine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Lacidipine.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Lacidipine.Approved, Investigational
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Lacidipine.Investigational
ValdecoxibThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Lacidipine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Lacidipine.Approved
VecuroniumLacidipine may increase the neuromuscular blocking activities of Vecuronium.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Lacidipine.Approved
VerapamilVerapamil may increase the hypotensive activities of Lacidipine.Approved
VincamineLacidipine may increase the hypotensive activities of Vincamine.Experimental
VoriconazoleThe serum concentration of Lacidipine can be increased when it is combined with Voriconazole.Approved, Investigational
XipamideLacidipine may increase the hypotensive activities of Xipamide.Experimental
YohimbineYohimbine may decrease the antihypertensive activities of Lacidipine.Approved, Investigational, Vet Approved
ZaltoprofenThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZiprasidoneThe risk or severity of hypotension can be increased when Ziprasidone is combined with Lacidipine.Approved
ZofenoprilLacidipine may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Zomepirac.Withdrawn
ZuclopenthixolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Lacidipine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Lacidipine synthesis: C. Semeraro et al., DE 3529997; eidem, U.S. Patent 4,801,599 (1986, 1989 both to Glaxo).

General References
  1. McCormack PL, Wagstaff AJ: Lacidipine: a review of its use in the management of hypertension. Drugs. 2003;63(21):2327-56. [PubMed:14524737]
  2. Lee CR, Bryson HM: Lacidipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of hypertension. Drugs. 1994 Aug;48(2):274-96. [PubMed:7527328]
  3. Herbette LG, Gaviraghi G, Tulenko T, Mason RP: Molecular interaction between lacidipine and biological membranes. J Hypertens Suppl. 1993 Mar;11(1):S13-9. [PubMed:8387105]
  4. Ishii N, Matsumura T, Shimoda S, Araki E: Anti-atherosclerotic potential of dihydropyridine calcium channel blockers. J Atheroscler Thromb. 2012;19(8):693-704. Epub 2012 May 17. [PubMed:22653165]
  5. Cerbai E, Giotti A, Mugelli A: Characteristics of L-type calcium channel blockade by lacidipine in guinea-pig ventricular myocytes. Br J Pharmacol. 1997 Feb;120(4):667-75. doi: 10.1038/sj.bjp.0700951. [PubMed:9051306]
  6. Lacidipine Summary of Product Characteristics [Link]
External Links
KEGG Drug
D04657
PubChem Compound
5311217
PubChem Substance
310265140
ChemSpider
4470736
ChEBI
135737
ChEMBL
CHEMBL460291
Wikipedia
Lacidipine
ATC Codes
C08CA09 — Lacidipine
MSDS
Download (78.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHealthy Volunteers4
2CompletedTreatmentAngina Pectoris1
3CompletedTreatmentHigh Blood Pressure (Hypertension)1
4CompletedTreatmentHigh Blood Pressure (Hypertension)2
4CompletedTreatmentHypertension,Essential / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableHigh Blood Pressure (Hypertension)1
Not AvailableTerminatedNot AvailableHigh Blood Pressure (Hypertension)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00224 mg/mLALOGPS
logP5.18ALOGPS
logP4.19ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)19.47ChemAxon
pKa (Strongest Basic)-6.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area90.93 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity129.91 m3·mol-1ChemAxon
Polarizability49.74 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00fr-0000900000-2964b6b69c71aeda6088
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0169400000-672099fb92e2023950eb

Taxonomy

Description
This compound belongs to the class of organic compounds known as cinnamic acid esters. These are compound containing an ester derivative of cinnamic acid.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Cinnamic acids and derivatives
Sub Class
Cinnamic acid esters
Direct Parent
Cinnamic acid esters
Alternative Parents
Tricarboxylic acids and derivatives / Dihydropyridinecarboxylic acids and derivatives / Styrenes / Fatty acid esters / Vinylogous amides / Enoate esters / Amino acids and derivatives / Enamines / Dialkylamines / Azacyclic compounds
show 4 more
Substituents
Cinnamic acid ester / Dihydropyridinecarboxylic acid derivative / Tricarboxylic acid or derivatives / Styrene / Dihydropyridine / Fatty acid ester / Monocyclic benzene moiety / Fatty acyl / Hydropyridine / Benzenoid
show 21 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...

Components:
References
  1. Cerbai E, Giotti A, Mugelli A: Characteristics of L-type calcium channel blockade by lacidipine in guinea-pig ventricular myocytes. Br J Pharmacol. 1997 Feb;120(4):667-75. doi: 10.1038/sj.bjp.0700951. [PubMed:9051306]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Lacidipine Summary of Product Characteristics [Link]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Lacidipine Summary of Product Characteristics [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Lacidipine Summary of Product Characteristics [Link]

Drug created on October 23, 2015 10:33 / Updated on August 02, 2018 06:16